Executive Summary

The global HAE therapeutic market is expected to grow at a significant rate over the next few years, driven by factors such as increasing awareness of the disease, growing demand for effective treatment options, and rising healthcare expenditure. The market is characterized by a high degree of competition, with several major players vying for market share. However, the market also presents significant opportunities for new entrants and smaller players, particularly in emerging markets.

Important Note: The companies listed in the image above are for reference only. The final study will cover 18–20 key players in this market, and the list can be adjusted based on our client’s requirements.

Key Market Insights

• The global HAE therapeutic market is expected to grow at a CAGR of 9.4% during the forecast period (2021-2028).
• North America is the largest market for HAE therapeutics, accounting for approximately 50% of the global market share.
• The market is highly competitive, with several major players such as CSL Behring, Takeda Pharmaceutical Company Limited, and Shire (now part of Takeda) dominating the market.
• Increasing awareness of the disease and growing demand for effective treatment options are driving market growth.
• The high cost of HAE therapeutics and limited access to healthcare in some regions are major challenges facing the market.

Market Drivers

1. Growing prevalence of HAE: The incidence of HAE is increasing globally, with an estimated 1 in 10,000 people affected by the disease. This is driving demand for effective treatment options and contributing to market growth.
2. Increasing awareness of the disease: Awareness of HAE is increasing, both among patients and healthcare professionals. This is leading to earlier diagnosis and treatment, which is improving patient outcomes and driving market growth.
3. Rising healthcare expenditure: Healthcare expenditure is increasing globally, particularly in emerging markets. This is enabling greater access to healthcare and contributing to market growth.

Market Restraints

1. High cost of HAE therapeutics: HAE therapeutics are expensive, which can limit patient access to treatment and negatively impact market growth.
2. Limited access to healthcare in some regions: Limited access to healthcare in some regions can hinder the growth of the HAE therapeutic market, particularly in emerging markets.

Market Opportunities

1. Emerging markets: Emerging markets present significant opportunities for growth in the HAE therapeutic market. These regions have large populations and increasing healthcare expenditure, which is driving demand for effective treatment options.
2. New product launches: New product launches present opportunities for market growth, particularly if these products offer significant improvements in efficacy and safety compared to existing treatments.

Market Dynamics

The HAE therapeutic market is highly competitive, with several major players vying for market share. The market is characterized by high R&D expenditure, with companies investing significant resources in developing new and improved treatments. The market is also subject to stringent regulatory requirements, particularly in developed markets such as the US and Europe.

Regional Analysis

North America is the largest market for HAE therapeutics, accounting for approximately 50% of the global market share. Europe is the second-largest market, followed by the Asia Pacific region. Emerging markets such as China, India, and Brazil present significant opportunities for growth in the HAE therapeutic market, driven by increasing healthcare expenditure and growing awareness of the disease.

Competitive Landscape

Leading companies in the Hereditary Angioedema Therapeutic market:

1. Takeda Pharmaceutical Company Limited
2. CSL Behring
3. Pharming Group N.V.
4. BioCryst Pharmaceuticals, Inc.
5. Ionis Pharmaceuticals, Inc.
6. Attune Pharmaceuticals
7. Adverum Biotechnologies, Inc.
8. Pharvaris B.V.
9. Centogene N.V.
10. KalVista Pharmaceuticals, Inc.

Please note: This is a preliminary list; the final study will feature 18–20 leading companies in this market. The selection of companies in the final report can be customized based on our client’s specific requirements.

Segmentation

The HAE therapeutic market can be segmented based on product type, route of administration, distribution channel, and geography. Product types include C1 esterase inhibitors, bradykinin receptor antagonists, and kallikrein inhibitors. Routes of administration include subcutaneous injection, intravenous infusion, and oral. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

Category-wise Insights

Based on product type, C1 esterase inhibitors are the most widely used treatment for HAE. These products account for the majority of the market share, with brands such as Berinert, Cinryze, and Ruconest leading the market. Bradykinin receptor antagonists and kallikrein inhibitors are newer treatment options, with products such as Firazyr and Kalbitor gaining popularity in recent years.

Key Benefits for Industry Participants and Stakeholders

Industry participants and stakeholders in the HAE therapeutic market stand to benefit in several ways, including:

• Growing demand for effective treatment options, which is driving market growth
• Increasing awareness of the disease, leading to earlier diagnosis and treatment
• Emerging markets presenting significant opportunities for growth
• High R&D expenditure, with companies investing significant resources in developing new and improved treatments
• Stringent regulatory requirements, which help to ensure product safety and efficacy

SWOT Analysis

Strengths:

• Growing demand for effective treatment options
• High R&D expenditure
• Increasing awareness of the disease

Weaknesses:

• High cost of HAE therapeutics
• Limited access to healthcare in some regions

Opportunities:

• Emerging markets presenting significant opportunities for growth
• New product launches

Threats:

• Stringent regulatory requirements
• Competition from existing and new players

Market Key Trends

Some of the key trends in the HAE therapeutic market include:

1. New product launches: Several new HAE therapeutics have been launched in recent years, offering patients more treatment options and driving market growth.
2. Personalized medicine: Advances in genetic testing and personalized medicine are enabling more targeted and effective treatment of HAE.
3. Combination therapies: Combination therapies, which combine different types of HAE therapeutics, are becoming more common and may offer greater efficacy than single-agent therapies.

Covid-19 Impact

The Covid-19 pandemic has had a mixed impact on the HAE therapeutic market. On the one hand, the pandemic has led to disruptions in supply chains and reduced patient access to healthcare in some regions, which has negatively impacted market growth. On the other hand, the pandemic has also led to increased awareness of the importance of effective healthcare and may have accelerated the adoption of telemedicine and other digital healthcare solutions, which could benefit the HAE therapeutic market in the long term.

Key Industry Developments

Some of the key developments in the HAE therapeutic market include:

1. Launch of new therapies: Several new HAE therapeutics have been launched in recent years, including Takhzyro, Haegarda, and Orladeyo.
2. Advances in gene therapy: Advances in gene therapy are offering the potential for more targeted and effective treatment of HAE.

Analyst Suggestions

Analysts suggest that companies operating in the HAE therapeutic market should focus on developing new and improved treatments with greater efficacy and safety profiles. They also suggest that companies should focus on expanding their presence in emerging markets, which present significant opportunities for growth.

Future Outlook

The future outlook for the HAE therapeutic market is positive, with the market expected to grow at a significant rate over the next few years. Increasing awareness of the disease, growing demand for effective treatment options, and rising healthcare expenditure are expected to drive market growth. However, the market is also subject to several challenges, including the high cost of HAE therapeutics and limited access to healthcare in some regions.

Conclusion

The HAE therapeutic market is a rapidly growing segment of the global pharmaceutical industry, driven by increasing awareness of the disease and growing demand for effective treatment options. The market is highly competitive, with several major players vying for market share. Emerging markets present significant opportunities for growth, while new product launches and advances in gene therapy offer the potential for more targeted and effective treatment of HAE. Despite challenges such as the high cost of HAE therapeutics and limited access to healthcare in some regions, the future outlook for the market is positive, with significant opportunities for industry participants and stakeholders.